Login / Signup

Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials.

Yosuke KaburagiKazunobu KiraKenzo YahataKentaro IsoYuki SatoFumiyoshi MatsuuraIsao OhashiYasunobu MatsumotoMinetaka IsomuraTakeo SasakiTakashi FukuyamaYusuke MiyashitaHiroshi AzumaDaisuke IidaTasuku IshidaWataru ItanoMasaaki MatsudaMasayuki MatsukuraNorio MuraiSatoshi NagaoMasashi SekiAkihiko YamamotoYuji YamamotoNaoki YonedaYuzo WatanabeAtsushi KamadaAkio KayanoKatsuya TagamiOsamu AsanoTakashi OwaYoshito Kishi
Published in: Organic letters (2024)
E7130 is a novel drug candidate with an exceedingly complex chemical structure of the halichondrin class, discovered by a total synthesis approach through joint research between the Kishi group at Harvard University and Eisai. Only 18 months after completion of the initial milligram-scale synthesis, ten-gram-scale synthesis of E7130 was achieved, providing the first good manufacturing practice (GMP) batch to supply clinical trials. This paper highlights the challenges in developing ten-gram-scale synthesis from the milligram-scale synthesis.
Keyphrases
  • clinical trial
  • gram negative
  • emergency department
  • primary care
  • randomized controlled trial
  • escherichia coli
  • multidrug resistant
  • drug induced